Reason for request
Inclusion on the list of medicines reimbursed by National Health Insurance and approved for use by hospitals.
Clinical Benefit
| Substantial |
The actual benefit of BYETTA is substantial. |
Clinical Added Value
| minor |
BYETTA provides a minor improvement in actual benefit (IAB IV) in the management of type-2 diabetes in patients treated with a combination of metformin and hypoglycaemic sulphonylurea who have not achieved adequate blood glucose control at the highest tolerated doses of these treatments. |
eNq1mF1v2jAUhu/5FVEudkdCoHx0S0AboxtSqzFatGk3yCSHYhbs1B987NfPIaDSyVFXgy8TJ+859jl+/Mphb7tKnTUwjimJ3MCruQ6QmCaYPEbu5OGm2nF73Uq4RGt08lnbq3lB3XXiFHEeufmoNwNEuPfz7vYzqP+Bud2KE9LZEmLx4jspcOp9RXxxh7L8GydcU5w4KxALmkRuJsX+rRNywVQW3Q1lv3mGYgj9w5vT0eX06vR96Odi/6EqObBbRB61okCMNGPJGBDRRwIeKduV5Nsw0sZ8DJxKFsMIicWI0TVOINGGmKOUg1GQ+Sa5B7ZOQeRBtOL+Ml5xI3G0RNsxPA31SX9Uo32xFdVaNWh3gut6u95p12sto1DsZKn0VVCT8ONpM2i3rmo+EH+2AyGQYWVGlAmUWqoJ5v2XbWUpDoOnV2ufYJ6laOcteWa6VIghNQxMbX57E8ln8MAUjlK1Zv/oE5mm/huznhxgYSnjnEV9KokoYcbN2HQh+pQI2JZX1AxzYnvoRQz8crJ/KNEjfiRnKY5NgaaQI4GLyXhYzrPLoeAT4jBh9ljwA5OEbvjlGXNaU0vZZ3tMakUzlgTT+nWnFTSbxlvol2qgktNlIBnNwFf0wfwcqAzJnJ6LE9WTeqljR16oGfcOh8YohRKPUzXkiurCoyWz1uf29lAxoBX9MngwbY7vEtjufv+olcZJdCyrGXNtgFx14mt5F3s2yqaNWrNz3bh6h1bZh6N3jgx9ciFqxSZLpgfMQoiMv/f9zWbjLRCvcqTW05uzMvz3tBO/xOQVa59rac/HWzn5CydUcNZS6rPiAH1bEU137Wve4Fy/e/j/4Ku1MQSTcEYtCsBbw/BwcHmyP5tda2mPXgDGXpi9MUUCU2LLMsmZVvGss0SVldwwxYdv8zkuuVYpbcvQL650upXQz69zupW/oDT9gQ==
WrLWDM8ZMY3VSQ0K
